| Followers | 40 |
| Posts | 4475 |
| Boards Moderated | 0 |
| Alias Born | 02/28/2018 |
Friday, November 27, 2020 10:23:07 AM
We Are the First and We Own a Game Changing Patent
MASSIVE BREAKTHROUGH
https://edtimes.in/sunshine-biopharma-makes-massive-breakthrough-to-tackle-the-deadly-coronavirus/
The team at Sunshine Biopharma was the first company to evaluate the SARS-CoV-2 protein PLpro, the virus that causes COVID-19 and destroys a human’s immune system. The compounds which were screened recently are based on the technology described in Sunshine Biopharma’s recently filed patent application covering small molecules which can be used to treat Coronavirus infections.
In September 2020
Ed Time Says
Moreover, Sunshine Biopharma is also developing its flagship anti-cancer compound called Adva-27a which is meant to destroy multidrug resistant cancer cells, including pancreatic cancer cells, small-cell lung cancer cells, breast cancer cells and uterine sarcoma cells. The mechanism by which Adva-27a is able to destroy cancer cells is through the inhibition of a key cell-cycle enzyme called Topoisomerase II. With thorough research, Sunshine Biopharma is running several clinical trials to curb these life-threatening diseases and the company is looked by the major pharmaceuticals of the world.
MASSIVE BREAKTHROUGH
https://edtimes.in/sunshine-biopharma-makes-massive-breakthrough-to-tackle-the-deadly-coronavirus/
The team at Sunshine Biopharma was the first company to evaluate the SARS-CoV-2 protein PLpro, the virus that causes COVID-19 and destroys a human’s immune system. The compounds which were screened recently are based on the technology described in Sunshine Biopharma’s recently filed patent application covering small molecules which can be used to treat Coronavirus infections.
In September 2020
Ed Time Says
Moreover, Sunshine Biopharma is also developing its flagship anti-cancer compound called Adva-27a which is meant to destroy multidrug resistant cancer cells, including pancreatic cancer cells, small-cell lung cancer cells, breast cancer cells and uterine sarcoma cells. The mechanism by which Adva-27a is able to destroy cancer cells is through the inhibition of a key cell-cycle enzyme called Topoisomerase II. With thorough research, Sunshine Biopharma is running several clinical trials to curb these life-threatening diseases and the company is looked by the major pharmaceuticals of the world.
Recent SBFM News
- Sunshine Biopharma Reports Fiscal 2025 Revenue of $36.3 Million, a 4.1% Increase Over Prior Year • ACCESS Newswire • 04/06/2026 12:30:00 PM
- Sunshine Biopharma Gains FDA-Equivalent Clearance in Canada for Domperidone to Treat Cancer-related Nausea • ACCESS Newswire • 10/28/2025 11:45:00 AM
- Sunshine Biopharma Launches STD, Acne and Lyme Disease Therapy Doxycycline • ACCESS Newswire • 10/20/2025 11:45:00 AM
- Sunshine Biopharma Launches Cholesterol Fighting Medicine Pravastatin • ACCESS Newswire • 10/16/2025 11:45:00 AM
- Sunshine Biopharma Allocates $5 Million for Investment in Bitcoin as Strategic Reserve Asset to Enhance Treasury Resilience • ACCESS Newswire • 10/14/2025 11:00:00 AM
- Sunshine Biopharma and University of Arizona Develop a Potent New Series of Protease Inhibitors for Treatment of SARS Coronavirus Infections • ACCESS Newswire • 10/09/2025 12:00:00 PM
